Overview

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

Status:
Completed
Trial end date:
2020-10-28
Target enrollment:
Participant gender:
Summary
The goal for this study is to evaluate the efficacy and safety of tirzepatide versus placebo in participants with type 2 diabetes not under control with diet and exercise alone. The study will last approximately 47 weeks and may include about 15 visits.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Gastric Inhibitory Polypeptide
Tirzepatide